Outcome of the Board Meeting - Financial Results
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rubicon Research Limited reported strong FY2026 results with consolidated revenue from operations growing 36.6% to ₹17,539.56 million from ₹12,842.72 million in FY2025. Net profit after tax surged 83.6% to ₹2,467.35 million compared to ₹1,343.61 million in the prior year. The company completed its IPO in October 2025 raising ₹13,775 million, with shares listed on NSE and BSE. Deloitte Haskins & Sells LLP issued an unmodified (clean) audit opinion on both standalone and consolidated results. The Board recommended a dividend of ₹1.50 per equity share for FY2026, subject to shareholder approval at the AGM. The company operates in the pharmaceutical products segment with 14 subsidiaries across multiple countries.
Strong financial performance with PAT growth exceeding 83% signals robust operational execution. The clean audit opinion and maiden dividend post-IPO are positive signals for shareholders, though the high valuation post-IPO may already reflect these gains.